课题基金 / 基金详情

VIROLOGIC RESPONSE TO NEW NUCLEOSIDE REGIMENS AFTER PROLONGED ZDV OR DDI IN HIV

VIROLOGIC RESPONSE TO NEW NUCLEOSIDE REGIMENS AFTER PROLONGED ZDV OR DDI IN HIV
HIV 长期 ZDV 或 DDI 后对新核苷治疗方案的病毒学反应
批准号：
6113831
负责人：
Joseph J Eron
金额：
$1.58万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6113831
关键词：
2'3' dideoxyinosine AIDS therapy HIV infections antiAIDS agent clinical research clinical trials drug resistance human immunodeficiency virus human subject human therapy evaluation lamivudine nucleoside analog stavudine virus RNA zidovudine

项目摘要

项目成果

Joseph J Eron的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ACTG 302 - The purpose of the study is to determine the influence of HIV virius load, characteristics of the virus and the presence of symptoms on response to new therapeutic regimens and on the development of ciral resistance mutation in HIV infected individuals who have been treated with monotherapy with either ZDV or ddI on a previous ACTG trial (ACTG 175). More specifically, this study will determine whether the addition of 3TC or a change to d4T in patients who have been ZDV result in a more rapid or durable suppression of plasma viral RNA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV/AIDS Clinical Trials Unit (CTU) COVID-19 Admin Supplement
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit
Clinical Core
Clinical Core
海外基金